Recent Updates
Recently added Catalysts
ATHE Neutral Sentiment Score: 60/100

Appendix 3Y Change of Director's Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director's Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documen

Thursday, April 10, 2025 4 min read
Key Takeaway: Alterity Therapeutics Limited has filed a Change of Director's Interest Notice regarding recent securities held by its directors. Peter Marks, Lawrence Gozlan, and Brian Meltzer have reported changes in their holdings, with notable acquisitions of fully paid ordinary shares. The notice reflects compliance with ASX regulations, emphasizing ongoing transparency in director interests within the company. No disposals were reported, indicating stable confidence in their holdings.

Market Sentiment Analysis

POSITIVE FACTORS

  • Director's significant acquisition of fully paid ordinary shares.
  • The notice is compliant with ASX regulations, ensuring transparency.
  • Alterity Therapeutics Limited continues to maintain detailed disclosure of director interests.

Full Press Release Details

Change of Director's
Change of Director's Interest Notice
Information or documents not available now must be given to ASX
as soon as available. Information and documents given to ASX becomes ASX's property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity Alterity Therapeutics Limited
ABN 37 080 699 065
We (the entity) give ASX the following information under listing rule
3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
Name of director Peter Marks
Date of last notice 30 December 2024
Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust
made available by the responsible entity of the trust
Note: In the case of a company, interests which
come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.
Direct or indirect interest (1) Indirect - Lampam Pty Ltd (2) Direct (3) Indirect - Shanti Capital Pty Ltd <Peter Marks Super Fund A/C>
Nature of indirect interest (including registered holder) (1) Director (2) N/A (3) SMSF
Date of change (1.1) N/A (1.2) N/A (2.1) N/A (2.2) N/A (3) 07 April 2025
No. of securities held prior to change (1.1) 7,185,968 - FULLY PAID ORDINARY SHARES (1.2) 2,380,952 - LISTED OPT EXP 31/08/2026 @ $0.01 (2.1) 7,000,000 - UNLISTED OPT EXP 17/09/2025 @ $0.09 (2.2) 30,000,000 - UNLISTED OPT EXP 30/12/2027 @ $0.01 (3) NIL - FULLY PAID ORDINARY SHARES
+ See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 1
Change of Director's
Class (1.1) FULLY PAID ORDINARY SHARES (1.2) LISTED OPT EXP 31/08/2026 @ $0.01 (2.1) UNLISTED OPT EXP 17/09/2025 @ $0.09 (2.2) UNLISTED OPT EXP 30/12/2027 @ $0.01 (3) FULLY PAID ORDINARY SHARES
Number acquired (1.1) NIL (1.2) NIL (2.1) NIL (2.2) NIL (3) 1,818,182 - FULLY PAID ORDINARY SHARES
Number disposed (1.1) NIL (1.2) NIL (2.1) NIL (2.2) NIL (3) NIL
Value/Consideration (1.1) N/A (1.2) N/A (2.1) N/A (2.2) N/A (3) $20,000 - $0.011 PER ORDINARY SHARE
No. of securities held after change (1.1) 7,185,968 - FULLY PAID ORDINARY SHARES (1.2) 2,380,952 - LISTED OPT EXP 31/08/2026 @ $0.01 (2.1) 7,000,000 - UNLISTED OPT EXP 17/09/2025 @ $0.09 (2.2) 30,000,000 - UNLISTED OPT EXP 30/12/2027 @ $0.01 (3) 1,818,182 - FULLY PAID ORDINARY SHARES
Nature of change (1.1) N/A (1.2) N/A (2.1) N/A (2.2) N/A (3) Placement @ $0.011 - Direct
Part 2 - Change of director's relevant interests in contracts
Note: In the case of a company, interests which come within paragraph
(ii) of the definition of "notifiable interest of a director" should be disclosed in this part.
Detail of contract N/A
Nature of interest N/A
Name of registered holder (if issued securities) N/A
Date of change N/A
No. and class of securities to which interest related prior to change N/A
Interest acquired N/A
Interest disposed N/A
Value/Consideration N/A
Interest after change N/A
+ See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 2
Part 3 - +Closed period
Were the interests in the securities or c+ontracts detailed above traded during a closed period where prior written clearance was required? No
If so, was prior written clearance provided to allow the trade to proceed during this period? N/A
If prior written clearance was provided, on what date was this provided? N/A
+ See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 3
Change of Director's
Change of Director's Interest Notice
Information or documents not available now must be given to ASX
as soon as available. Information and documents given to ASX becomes ASX's property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity Alterity Therapeutics Limited
ABN 37 080 699 065
We (the entity) give ASX the following information under listing rule
3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
Name of director Lawrence Gozlan
Date of last notice 30 December 2024
Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made
available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph
(i) of the definition of "notifiable interest of a director" should be disclosed in this part.
Direct or indirect interest (1) Direct (2) Indirect - Montoya Pty Ltd <Buttercup A/C>
Nature of indirect interest (including registered holder) (1) N/A (2) Director
Date of change (1.1) N/A (1.2) N/A (2) 07 April 2025
No. of securities held prior to change (1.1) 7,000,000 - UNLISTED OPT EXP 17/09/2025 @ $0.09 (1.2) 50,000,000 - UNLISTED OPT EXP 30/12/2027 @ $0.01 (2) NIL - FULLY PAID ORDINARY SHARES
Class (1.1) UNLISTED OPT EXP 17/09/2025 @ $0.09 (1.2) UNLISTED OPT EXP 30/12/2027 @ $0.01 (2) FULLY PAID ORDINARY SHARES
Number acquired (1.1) NIL (1.2) NIL (2) 4,545,455 - FULLY PAID ORDINARY SHARES
+ See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 1
Change of Director's
Number disposed (1.1) NIL (1.2) NIL (2) NIL
Value/Consideration (1.1) N/A (1.2) N/A (2) $50,000 - $0.011 PER FULLY PAID ORDINARY SHARE
No. of securities held after change (1.1) 7,000,000 - UNLISTED OPT EXP 17/09/2025 @ $0.09 (1.2) 50,000,000 - UNLISTED OPT EXP 30/12/2027 @ $0.01 (2) 4,545,455 - FULLY PAID ORDINARY SHARES
Nature of change (1.1) N/A (1.2) N/A (2) Placement @ $0.011
Part 2 - Change of director's relevant interests in contracts
Note: In the case of a company, interests which come within paragraph
(ii) of the definition of "notifiable interest of a director" should be disclosed in this part.
Detail of contract N/A
Nature of interest N/A
Name of registered holder (if issued securities) N/A
Date of change N/A
No. and class of securities to which interest related prior to change N/A
Interest acquired N/A
Interest disposed N/A
Value/Consideration N/A
Interest after change N/A
Part 3 - +Closed period
Were the interests in the securities or c+ontracts detailed above traded during a closed period where prior written clearance was required? No.
If so, was prior written clearance provided to allow the trade to proceed during this period? N/A
If prior written clearance was provided, on what date was this provided? N/A
+ See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 2
Change of Director's
Change of Director's Interest Notice
Information or documents not available now must be given to ASX
as soon as available. Information and documents given to ASX becomes ASX's property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity Alterity Therapeutics Limited
ABN 37 080 699 065
We (the entity) give ASX the following information under listing rule
3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
Name of director Brian Meltzer
Date of last notice 30 December 2024
Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made
available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph
(i) of the definition of "notifiable interest of a director" should be disclosed in this part.
Direct or indirect interest (1) Direct (2) Indirect - BT PORTFOLIO SERVICES
Nature of indirect interest (including registered holder) (1) N/A (2) SMSF
Date of change (1.1) 07 April 2025 (1.2) N/A (1.3) N/A (1.4) N/A (2) N/A
No. of securities held prior to change (1.1) 7,142,857 - FULLY PAID ORDINARY SHARES (1.2) 2,380,952 - LISTED OPT EXP 31/08/2026 @ $0.01 (1.3) 7,000,000 - UNLISTED OPT EXP 17/09/2025 @ $0.09 (1.4) 30,000,000 - UNLISTED OPT EXP 30/12/2027 @ $0.01 (2) 326,666 - FULLY PAID ORDINARY SHARES
+ See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 1
Change of Director's
Class (1.1) FULLY PAID ORDINARY SHARES (1.2) LISTED OPT EXP 31/08/2026 @ $0.01 (1.3) UNLISTED OPT EXP 17/09/2025 @ $0.09 (1.4) UNLISTED OPT EXP 30/12/2027 @ $0.01 (2) FULLY PAID ORDINARY SHARES
Number acquired (1.1) 2,272,727 - FULLY PAID ORDINARY SHARES (1.2) NIL (1.3) NIL (1.4) NIL (2) NIL
Number disposed (1.1) NIL (1.2) NIL (1.3) NIL (1.4) NIL (2) NIL
Value/Consideration (1.1) $25,000 - $0.011 PER FULLY PAID ORDINARY SHARE (1.2) N/A (1.3) N/A (1.4) N/A (2) N/A
No. of securities held after change (1.1) 9,415,584 - FULLY PAID ORDINARY SHARES (1.2) 2,380,952 - LISTED OPT EXP 31/08/2026 @ $0.01 (1.3) 7,000,000 - UNLISTED OPT EXP 17/09/2025 @ $0.09 (1.4) 30,000,000 - UNLISTED OPT EXP 30/12/2027 @ $0.01 (2) 326,666 - FULLY PAID ORDINARY SHARES
Nature of change (1.1) Placement @ $0.011 - Direct (1.2) N/A (1.3) N/A (1.4) N/A (2) N/A
Part 2 - Change of director's relevant interests in contracts
Note: In the case of a company, interests which come within paragraph
(ii) of the definition of "notifiable interest of a director" should be disclosed in this part.
+ See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 2
Change of Director's
Detail of contract N/A
Nature of interest N/A
Name of registered holder (if issued securities) N/A
Date of change N/A
No. and class of securities to which interest related prior to change N/A
Interest acquired N/A
Interest disposed N/A
Value/Consideration N/A
Interest after change N/A
Part 3 - +Closed period
Were the interests in the securities or c+ontracts detailed above traded during a closed period where prior written clearance was required? No
If so, was prior written clearance provided to allow the trade to proceed during this period? N/A
If prior written clearance was provided, on what date was this provided? N/A
+ See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 3

Frequently Asked Questions

What is the purpose of the Change of Director's Interest Notice?

The notice informs ASX of changes in a director's relevant interests in securities.

Who is the director mentioned in the notice?

The directors mentioned include Peter Marks, Lawrence Gozlan, and Brian Meltzer.

What changes occurred for Peter Marks on 07 April 2025?

Peter Marks acquired 1,818,182 fully paid ordinary shares at $0.011 each.

How many shares did Lawrence Gozlan acquire?

Lawrence Gozlan acquired 4,545,455 fully paid ordinary shares at a price of $0.011.

What does 'indirect interest' entail?

Indirect interest includes stakes held through related entities, like trusts.

Tags: ATHE Viatris Investor Conferences Healthcare Alterity Therapeutics director interests ASX securities
Last updated: Apr 10, 2025